Through ChIP-seq analysis, we identified the DOT1L targets shared between MLL-r and non-MLL-r AML cells that play relevant roles in cancer biology, including RAF1 and BRAF, which encode for RAF/MEK/ERK signaling members inhibited by Sorafenib, and we validated the notion that strong BRAF down-modulation is a mechanism by which Pinometostat enhances Sorafenib efficacy. This evidence concerns the gene KMT2A and cancer.